Bortezomib abrogates temozolomide-induced autophagic flux through an ATG5 dependent pathway

Introduction: Glioblastoma (GBM) is invariably resistant to temozolomide (TMZ) chemotherapy. Inhibiting the proteasomal pathway is an emerging strategy to accumulate damaged proteins and inhibit their lysosomal degradation. We hypothesized that pre-treatment of glioblastoma with bortezomib (BTZ) mig...

Full description

Bibliographic Details

Published in:	Frontiers in Cell and Developmental Biology
Main Authors:	Mohummad Aminur Rahman, Agnete S. T. Engelsen, Shahin Sarowar, Christian Bindesbøll, Even Birkeland, Dorota Goplen, Maria L. Lotsberg, Stian Knappskog, Anne Simonsen, Martha Chekenya
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Subjects:	glioblastoma (GBM) proteasome inhibitor bortezomib secretome temozolomide chemotherapy cell cycle kinetics autophagy flux
Online Access:	https://www.frontiersin.org/articles/10.3389/fcell.2022.1022191/full